Cargando…
Biomarker-based corticosteroid adjustment in severe asthma: a modified Delphi consensus
UK asthma physicians are supportive of biomarker-based steroid adjustment, but European physicians need more evidence http://ow.ly/sTrf30my3jw
Autores principales: | Gallagher, Nicola E., Hanratty, Catherine E., Humbert, Marc, Bel, Elisabeth, Djukanovic, Ratko, Hudson, Valerie, Amos, Nile, Heaney, Liam G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284095/ https://www.ncbi.nlm.nih.gov/pubmed/30538996 http://dx.doi.org/10.1183/23120541.00081-2018 |
Ejemplares similares
-
A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial
por: Hanratty, Catherine E., et al.
Publicado: (2018) -
Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
por: Menzies-Gow, Andrew, et al.
Publicado: (2019) -
Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
por: Heaney, Liam G, et al.
Publicado: (2021) -
Advancing Understanding of Mechanisms of Severe Asthma and Drug Effects Using Transcriptomics
por: Djukanović, Ratko
Publicado: (2019) -
Using biomarkers to adjust corticosteroid dose in patients with severe asthma
por: Jones, Thomas L.
Publicado: (2021)